Cats are up, up and away with NEW Meloxidyl Oral ... › content › download › 5397 › 91144... · dosage and administration: Dogs: musculoskeletal disorders - single subcutaneous

Cats are up, up and away with NEW Meloxidyl® Oral Suspension for Cats

Dosage Guiden Maintenance dose is 0.05mg meloxicam/kg

bodyweight

n Tailored maintenance dosing syringe with a “kg scale” for all sizes of cat

n On the first day, a loading dose of twice the maintenance dose should be given

n 6 months shelf-life once opened

*To nearest day on maintenance dose.

n Available in 15ml bottles containing 0.5mg/ml meloxicam

n Sweet tasting formulation maximises ease of administration

n Licensed for the treatment of musculo-skeletal disorders and the alleviation of post-operative pain

New

ORAL SUSPENSION FOR CATS

®

MELOXIDYL® ORAL SUSPENSION FOR CATSAn easy to give oral liquid containing meloxicam

NEW

Clinical signs of osteoarthritis in the catReduced activity levels

Reduction in:n Playing/hunting

n Jumping and sleeping on high areas (e.g. bed, sofa, lap, work surfaces)

n Appetite

n Using scratching post - claws may become overgrown

n Self-grooming - fur can become matted

n Using litterbox - may pass faeces or urine in unusual places

Reduced interaction with the owner

Affected cats may:n Purr less

n Become resentful when handled/groomed

n Appear ‘moody’, ‘grumpy’ and withdrawn

Joint pain Overt lameness is often not present, but clinical signs may include:n Limping and stiff, stilted gait

n Thickened painful joints

Carprodyl® F tablets are scored, circular beige tablets containing as active ingredient 20 mg, 50 mg or 100 mg carprofen. Uses: For analgesia and reduction of chronic inflammation, for example in degenerative joint disease of the dog. Carprodyl® F tablets can also be used in the management of post-operative pain in dogs. Contra-indications: The elimination time of NSAIDs, including carprofen, in the cat is longer than in the dog and the therapeutic index is narrower. Consequently, do not use in cats. Do not use in pregnant or lactating bitches. Do not use in case of known hypersensitivity to active substance or to any of the excipients. Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product. Do not use in pups less than 4 months of age. precautions: Use in aged dogs may involve additional risk. If such a use cannot be avoided, dogs may require careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic drugs should be avoided. NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated. Do not administer other NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects. Response to long term treatment should be monitored at regular intervals by a veterinary surgeon. operator warning: In the event of accidental ingestion of the tablets, seek medical advice and show the doctor the package leaflet. Wash hands after handling the product. overdose: No signs of toxicity appeared when dogs were treated with carprofen at levels up to 6 mg/kg twice daily for 7 days (3 times the recommended dose rate of 4 mg/kg) and 6 mg/kg once daily for a further 7 days (1.5 times the recommended dose rate of 4 mg/kg). There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs, should be applied. Interaction with other medicinal products and other forms of interaction: Carprofen must not be administered with glucocorticoids. For animal treatment only. Keep out of reach and sight of children. pharmaceutical precautions: This medicinal product does not require any special temperature storage conditions. Store tablets and half-tablets in the original blister in order to protect from light. legal category: POM-V Marketing authorisation Number: Carprodyl® F 20 mg - Vm 15052/4033, Carprodyl® F 50 mg - Vm 15052/4034, Carprodyl® F 100 mg - Vm 15052/4035.

MEloXIdyl® is a pale yellow suspension containing 1.5mg/ml meloxicam as active ingredient and 2mg/ml of sodium benzoate as a preservative, for oral application to food. Use: The alleviation of inflammation and pain in acute and chronic musculo-skeletal disorders in dogs. Contra-indications: Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of individual hypersensitivity to the product. Do not use in dogs less than 6 weeks of age. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. The safety of the product has not been established during pregnancy and lactation. Special precautions for use: If side effects occur, treatment should be discontinued. In the case of overdose, symptomatic treatment should be initiated. operator warning: People with known hypersensitivity to NSAID’s should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician. adverse reactions: Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy

have occasionally been reported. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment, but in very rare cases may be serious or fatal. Interaction with other medicinal products and other forms of interaction: Other NSAIDs, diuretics, anticoagulants, aminoglycoside antimicrobials and substances with high protein binding may compete for binding and thus lead to toxic effects. The product must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously. pharmaceutical precautions: After broaching the container, the contents should be used within 6 months. If any unused product remains after this time, it should be disposed of in accordance with national regulations. legal category: POM-V Market authorisation number: EU/2/06/070/001 MELOXIDYL® 1.5mg/ml oral suspension for dog 10ml, EU/2/06/070/002 MELOXIDYL® 1.5mg/ml oral suspension for dogs 32ml, EU/2/06/070/003 MELOXIDYL® 1.gmg/ml oral suspension for dog 100ml.

MEloXIdyl 0.5 mg/ml Oral Suspension for Cats: Each ml contains 0.5 mg meloxicam. Indications: Alleviation of inflammation and pain in chronic musculo-skeletal disorders in cats. Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery. Contraindications: Do not use in pregnant or lactating animals. Do not use in cats suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not use in cats less than 6 weeks of age. Adverse reactions: Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. These side effects are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. precautions: Special precautions for use in animals: If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon. MELOXIDYL 0.5 mg/ml oral suspension for cats should not be used following parenteral injection of meloxicam or any other non-steroidal anti-inflammatory drugs (NSAIDs) as appropriate dosage regimens for such follow-up treatments have not been established in cats. The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Special precautions to be taken by the person administering the product: People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Interactions: Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. MELOXIDYL must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided. Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously. EU/2/06/070/008. POM-V.

MEloXIdyl® solution for injection contains 5mg/ml meloxicam as active ingredient and 150mg anhydrous ethanol as preservative. Use: Dogs: The alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. The reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery. Cats: The reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery. dosage and administration: Dogs: musculoskeletal disorders - single subcutaneous injection at a dosage of 0.2mg meloxicam/kg bodyweight; reduction of post-operative pain - single intravenous or subcutaneous injection at a dosage of 0.2mg meloxicam/kg bodyweight before surgery, for example at the time of induction of anaesthesia. Cats: reduction of post-operative pain - single subcutaneous injection at a dosage of 0.3mg meloxicam/kg bodyweight. Particular care should be taken with regard to the accuracy of dosing. Avoid introduction of contamination during use. Contra-indications, warnings, etc: Do not use in pregnant or lactating animals. Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg. Do not use an oral follow-up therapy using meloxicam or other NSAIDs in cats, as no safe dosage for repeated oral administration has been established. Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. In dogs, these side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. In very rare cases anaphylactoid reactions may occur and should be treated symptomatically. If adverse reactions occur, treatment should be discontinued. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Meloxidyl® must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided. In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration. When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded. In the case of overdosage symptomatic treatment should be initiated. For post-operative pain relief in cats, safety has only been documented after thiopental/halothane anaesthesia. operator warnings: Accidental self-injection may give rise to pain. People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or label to the physician. disposal advice: Any unused product or waste materials derived from the product should be disposed of in accordance with local requirements. For animal treatment only. Keep out of reach of children. pharmaceutical precautions: Shelf life of broached vial: 28 days. Do not use after the expiry date stated on the carton and on the bottle. Do not store above 25°C. legal category POM-V packaging quantities: Colourless glass injection vials of 10ml sealed with a rubber stopper and aluminium cap. Marketing authorisation number: EU/2/06/070/004.

FLEXIVET® PLUSAdvanced Joint Support Supplement

Administration

n Once daily administration

n May be added to food or given as a tasty treat

n After the initial 6 week loading period, reduce to half this amount for long-term maintenance

Ingredients

®

®

Active Ingredients Per Tablet

Amount (mg)

Green lipped mussel 600

Glucosamine hydrochloride 500

Methylsulphonylmethane 500

Manganese 30

Vitamin C 45

Bodyweight (kg)

Loading (first 6 weeks)

Maintenance (Long-term)

0 - 10 1 tablet ½ tablet

10 - 20 2 tablets 1 tablet

20 - 40 3 tablets 1 ½ tablets

> 40 4 tablets 2 tablets

Ceva Animal Health Ltd 90 The Broadway, Chesham, Bucks HP5 1EGTel: 01494 781510 Fax: 01494 781519www.ceva.com

MELOXIDYL® ORAL SUSPENSION FOR CATSAn easy to give oral liquid containing meloxicam

SUPPORT GUIDE

CevaJ O I N T C A R E

FLEXIVET® PLUSAdvanced Joint Support Supplement

MELOXIDYL® ORAL SUSPENSION FOR DOGSAn easy to give oral liquid containing meloxicam

Meloxidyl® Oral Suspension for Dogs

Leading Oral Meloxicam Product for Dogs

Efficacy ++ ++Palatability ++ ++Ease of use ++

Two syringes:Large syringe (dogs > 7 kg)Small syringe (dogs < 7 kg)

The small syringe enables easy and accurate measurement of the dose for small dogs without the need to count drops

+One syringe:Large syringe

For small dogs it is necessary to count drops from the bottle

A comparison between Meloxidyl® oral suspension for dogs and the leading oral meloxicam product for dogs:

n Available in 10ml, 32ml and 100ml bottles containing 1.5mg/ml meloxicam

n Sweet tasting formulation – equal palatability to the leading meloxicam product1

n Easy to administer – each pack contains two syringes- Large syringe - measures the dose for dogs over 7kg- Small syringe - measures the dose for dogs under 7kg, without the need to count drops

0.1 mg/kg Maintenance Dosage Table

Bodyweight(kg)

Meloxidyl®

0-7Dose according to bodyweight scale using the small syringe

>7Dose according to bodyweight scale using the large syringe

1. CEVA Study AP9/2.2, 2007.

CARPRODYL® FTasty pork flavoured tablets containing carprofen

MELOXIDYL® INJECTIONInjectable formulation containing meloxicam

n Available in 10ml bottles containing 5mg/ml meloxicam

n Licensed in cats and dogs for the reduction of post-operative pain

n Can be followed 24 hours later in the dog with Meloxidyl® oral suspension

Dosage Guide

n Dogs - single subcutaneous or intravenous injection at a dosage of 0.2mg meloxicam/kg bodyweight

n Cats - single subcutaneous injection at a dosage of 0.3mg meloxicam/kg bodyweight

Dog’s bodyweight(kg)

Intravenous or subcutaneous injection

volume (ml)

5 0.27.5 0.310 0.4

12.5 0.515 0.6

17.5 0.720 0.8

22.5 0.925 1.0

27.5 1.130 1.2

32.5 1.335 1.4

37.5 1.540 1.6

42.5 1.745 1.8

47.5 1.950 2.0

Cat’s bodyweight(kg)

Subcutaneous injection volume (ml)

2 0.122.5 0.153 0.18

3.5 0.214 0.24

4.5 0.275 0.30

5.5 0.336 0.36

6.5 0.397 0.42

7.5 0.458 0.48

8.5 0.51

NEW

CARPRODYL® FTasty pork flavoured tablets containing carprofen

Carprodyl® F Leading Carprofen Tablets

Efficacy ++ ++Flavouring Pork Pig liverPack sizes 20mg, 50mg and 100mg 20mg, 50mg and 100mgPackaging Blister packs Pots

Cost effective ++ +

4 mg/kg Dosage Table

Bodyweight(kg)

Carprodyl® F20mg

Carprodyl® F50mg

Carprodyl® F100mg

5

10

12.5

20

25

37.5

50

A comparison between Carprodyl® F and the leading carprofen product:

Dosage Guide

n 4 mg per kg bodyweight per day given as a single dose or in two equally divided doses

n The daily dose may be reduced after 7 days to 2mg/kg once daily, subject to clinical response

n Tasty pork flavour

- in palatability studies, 100% of dogs took the flavoured tablets voluntarily from the hand or in food2

n Professional blister presentation

- all tablets are protected

- accurate and straightforward dispensing

2. CEVA Study GAL/375BI/0513/1.5.2.3, 2008.